Holen Sie sich die Stockscreener-App
4.56
1.79%
0.08
Handel nachbörslich:
4.55
-0.010
-0.22%
Schlusskurs vom Vortag:
$4.48
Offen:
$4.48
24-Stunden-Volumen:
103.25K
Relative Volume:
0.45
Marktkapitalisierung:
$163.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+5.31%
1M Leistung:
+0.00%
6M Leistung:
+0.88%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.47
$4.58
1-Wochen-Bereich:
$4.25
$4.58
52-Wochen-Spanne:
$2.88
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
Firmenname
Bioage Labs Inc
Sektor
Telefon
510-806-1445
Adresse
5885 HOLLIS STREET, EMERYVILLE
Vergleichen Sie BIOA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
4.56 | 160.61M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
152.44 | 66.38B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.20B | 29.96B | 957.25M | 5.31B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.99B | 14.26B | 1.98B | 0 | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.63B | 2.99B | 1.21B | 1.13B | 25.06 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-12-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-21 | Eingeleitet | Citigroup | Buy |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-21 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
What is BioAge Labs Inc. s revenue forecast3x Potential Swing Trade Ideas - newsyoung.net
BioAge Labs Reports Q2 2025 Financial Results and Progress - TipRanks
Q3 EPS Estimates for BioAge Labs Decreased by William Blair - MarketBeat
Smart tools for monitoring BioAge Labs Inc.’s price actionAI-Powered Stock Trend Movement Analysis - Newser
What makes BioAge Labs Inc. stock price move sharplyFree Growth Focused Entry Plan Suggestions - Newser
Cautious Outlook on BioAge Labs, Inc. Amid Uncertainties in Clinical Developments and Market Perception - TipRanks
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M - The Motley Fool
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M - Nasdaq
BioAge Labs, Inc. Advances Clinical Pipeline with BGE-102 Phase 1 Trial Set for 2H 2025 and Expands APJ Agonist Pipeline - Quiver Quantitative
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
BioAge Labs Q2 2025: BGE-102 on track for Phase 1, expanded APJ pipeline, strengthened discovery platform. - AInvest
BioAge Labs Pipeline Expands: Key NLRP3 Drug Enters Clinical Phase, Secures 4-Year Cash Runway - Stock Titan
Full technical analysis of BioAge Labs Inc. stockFree Fundamental Growth Stock Analysis - Newser
What are the technical indicators suggesting about BioAge Labs Inc.Maximize your returns with expert insights - Jammu Links News
What catalysts could drive BioAge Labs Inc. stock higher in 2025Dynamic investment growth - Jammu Links News
What is BioAge Labs Inc. company’s growth strategyHigh-margin investment plays - Jammu Links News
How does BioAge Labs Inc. compare to its industry peersDiscover undervalued stocks before they soar - Jammu Links News
Is BioAge Labs Inc. a growth stock or a value stockSkyrocketing returns - Jammu Links News
Should I hold or sell BioAge Labs Inc. stock in 2025Rapid market gains - Jammu Links News
What are the latest earnings results for BioAge Labs Inc.Navigate the market with precision tools - Jammu Links News
BioAge Labs Requests to Dismiss Class Action Filed by Investors - TradingView
BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery - MSN
Published on: 2025-07-29 06:11:56 - beatles.ru
Price Channel Expanding on BioAge Labs Inc.’s ChartAccurate Buy Point for Momentum Stocks Detected - beatles.ru
BioAge to Analyze Over 17,000 Biobank Samples for Drug Discovery - AInvest
How to interpret RSI for BioAge Labs Inc. stockFree Trade Ready Stock Watch for Short Term - Newser
Published on: 2025-07-29 09:16:13 - metal.it
Can BioAge Labs Inc. Bounce Back From Weekly LowWeekly Top Gainers Forecast Watchlist Released - metal.it
Will BioAge Labs Inc. Benefit From Sector TailwindsReal Time Stock Movement Analysis Indicates Breakout - metal.it
Competitive Positioning of BioAge Labs Inc.: Is It Leading or LaggingLow Risk Entry Points - metal.it
How strong is BioAge Labs Inc. company’s balance sheetInvest confidently with data-backed picks - Jammu Links News
Finanzdaten der Bioage Labs Inc-Aktie (BIOA)
Es liegen keine Finanzdaten für Bioage Labs Inc (BIOA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):